Genetic Test for Opioid Use Disorder Risk Faces Accuracy Concerns
A study found that an FDA-approved genetic test for opioid use disorder risk may produce high rates of false positives and false negatives.
Read MorePosted by Andy Lundin | Jan 9, 2025 | Molecular Diagnostics |
A study found that an FDA-approved genetic test for opioid use disorder risk may produce high rates of false positives and false negatives.
Read MorePosted by Andy Lundin | Jan 9, 2025 | Cancer, Molecular Diagnostics |
Summary: A Mayo Clinic-led international study utilized CRISPR-Cas9 technology to classify 91% of...
Read MorePosted by Andy Lundin | Jan 8, 2025 | Molecular Diagnostics |
Myriad Genetics and MD Anderson Cancer Center are partnering to advance the development of a molecular residual disease (MRD) assay.
Read MorePosted by Andy Lundin | Jan 3, 2025 | Swabs |
The nasal swab test accurately diagnoses asthma endotypes, enabling more precise treatments and advancing research into asthma subtypes.
Read MorePosted by Andy Lundin | Dec 30, 2024 | Colorectal |
Mainz Biomed is collaborating with Quest Diagnostics to support the commercialization and FDA validation of a stool-based DNA test.
Read More